Journal
JOURNAL OF FUNGI
Volume 7, Issue 6, Pages -Publisher
MDPI
DOI: 10.3390/jof7060451
Keywords
fungal infections; fungus-specific T cells; T cell immunotherapy
Categories
Funding
- Research, Technology Development and Innovation (RTDI) State Aid Action RESEARCH-CREATE-INNOVATE
Ask authors/readers for more resources
Despite the availability of various antifungal drugs, opportunistic fungal infections pose a life-threatening risk to immunocompromised patients. Current antifungal drug therapy is limited by issues such as suboptimal efficacy and development of resistance, leading to the continuous advancement of adjunctive immunotherapies in combating invasive fungal infections.
Despite the availability of a variety of antifungal drugs, opportunistic fungal infections still remain life-threatening for immunocompromised patients, such as those undergoing allogeneic hematopoietic cell transplantation or solid organ transplantation. Suboptimal efficacy, toxicity, development of resistant variants and recurrent episodes are limitations associated with current antifungal drug therapy. Adjunctive immunotherapies reinforcing the host defense against fungi and aiding in clearance of opportunistic pathogens are continuously gaining ground in this battle. Here, we review alternative approaches for the management of fungal infections going beyond the state of the art and placing an emphasis on fungus-specific T cell immunotherapy. Harnessing the power of T cells in the form of adoptive immunotherapy represents the strenuous protagonist of the current immunotherapeutic approaches towards combating invasive fungal infections. The progress that has been made over the last years in this field and remaining challenges as well, will be discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available